AR and prostate carcinoma: As a result of the reduction of MBOAT1/2 expression, cells become sensitive to ferroptosis, which may be useful in combination with estrogen receptor (ER) and androgen receptor (AR) antagonists in the therapy of selected breast and prostate cancers [61].